178490-58-9

Basic information

• Product Name: 6-BroMo-4-phenylquinolin-2(1H)-one
• Synonyms: 6-BroMo-4-phenylquinolin-2(1H)-one;6-Bromo-4-phenyl-1H-quinolin-2-one
• CAS NO: 178490-58-9
• Molecular Formula: C₁₅H₁₀BrNO
• Molecular Weight: 300.15
• Mol File: 178490-58-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-BroMo-4-phenylquinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-4-phenylquinolin-2(1H)-one(178490-58-9)
• EPA Substance Registry System: 6-BroMo-4-phenylquinolin-2(1H)-one(178490-58-9)

Safety Data

• Hazardous Substances Data: 178490-58-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-4-phenylquinolin-2(1H)-one is used as a potential drug candidate for various therapeutic purposes due to its quinolone structure and properties. Quinolones have been known for their antimicrobial properties, and research on derivatives like 6-Bromo-4-phenylquinolin-2(1H)-one may lead to the development of novel drugs for treating various diseases and conditions.
Used in Medicinal Chemistry Research:
6-Bromo-4-phenylquinolin-2(1H)-one serves as a subject of interest in medicinal chemistry research, where its structure and properties are studied to explore its potential as a novel drug candidate. 6-BroMo-4-phenylquinolin-2(1H)-one's unique features, such as the bromine atom and phenyl group, may contribute to its therapeutic potential and pave the way for the development of new pharmaceuticals.

Upstream product

• 39859-36-4 2-amino-5-bromobenzophenone 
• 141-78-6 ethyl acetate 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 1373758-54-3 3-(4-methylphenyl)-5H-1,4,2-dioxazol-5-one 
• 189252-18-4 1-phenyl-1-(2-amino-5-bromophenyl)ethylene 
• 71787-43-4 N-(2-benzoyl-4-bromophenyl)acetamide 
• 1088-93-3 N-(4-bromophenyl)-3-oxo-3-phenylpropanamide 
• 861872-55-1 C₁₅H₁₀BrNO 

Downstream Products

• 393124-91-9 2-chloro-6-bromo-4-phenylquinoline 
• 1118761-83-3 C₁₆H₁₂BrNO 

Relevant articles and documents

NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF

A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

Metal-Free C-H [5 + 1] Carbonylation of 2-Alkenyl/Pyrrolylanilines Using Dioxazolones as Carbonylating Reagents

A novel metal-free C-H [5 + 1] carbonylative annulation of 2-alkenyl/pyrrolylanilines with dioxazolones has been established for the assembly of the privileged quinolinones and pyrrolyl-fused quinoxalinones. Entirely differing from the existing reports, the dioxazolones herein behave with an innovative chemistry and first emerge as carbonylating reagents to participate in annulation reactions. Moreover, this process features exceedingly simple operation (only solvent) and tolerates both vinyl and aryl substrates. Comprehensive mechanistic studies indicate that the formed isocyanate intermediate plays a crucial role in enabling the carbonylation annulation.

Rational modification of a candidate cancer drug for use against chagas disease

Chagas disease is one of the major neglected diseases of the world. Existing drug therapies are limited, ineffective, and highly toxic. We describe a novel strategy of drug discovery of adapting an existing clinical compound with excellent pharmaceutical properties to target a pathogenic organism. The protein farnesyltransferase (PFT) inhibitor tipifarnib, now in phase III anticancer clinical trials, was previously found to kill Trypanosoma cruzi by blocking sterol 14a-demethylase (14DM). We rationally developed tipifarnib analogues that display reduced affinity for human PFT to reduce toxicity while increasing affinity for parasite 14DM. The lead compound has picomolar activity against cultured T. cruzi and is efficacious in a mouse model of acute Chagas disease.

Synthesis and anticonvulsant activity of 5-phenyl-[1,2,4]-triazolo[4,3-a] quinolines

A series of novel 5-phenyl-[1,2,4]-triazolo[4,3-a]quinoline derivatives was synthesized by the cyclization of 2-chloro-4-phenyl-1,2-dihydronaphthalene with formohydrazide. The starting material 2-chloro-4-phenyl-1,2-dihydronaphthalene was synthesized from ethyl-3-oxo-3-phenylpropanoate and substituted aniline. Their anticonvulsant activities were evaluated by the maximal electroshock (MES) test and their neurotoxicity was evaluated by the rotarod neurotoxicity test (Tox). The maximal electroshock test showed that 7-hexyloxy-5-phenyl-[1,2,4]- triazolo[4,3-a]quinoline 4f was found to be the most potent compound with an ED50 value of 6.5 mg/kg and a protective index (PI = ED 50/TD50) value of 35.1, which was much higher than the PI of the reference drug phenytoin.

QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS

Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of Formula (Ia) or (Ib), a pharmaceutically acce

QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemic